0001209191-19-020792.txt : 20190321 0001209191-19-020792.hdr.sgml : 20190321 20190321164755 ACCESSION NUMBER: 0001209191-19-020792 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190320 FILED AS OF DATE: 20190321 DATE AS OF CHANGE: 20190321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MERRIWEATHER ALFRED G CENTRAL INDEX KEY: 0001211839 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 19697554 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-20 0 0001328143 Adamas Pharmaceuticals Inc ADMS 0001211839 MERRIWEATHER ALFRED G C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 0 1 0 0 Chief Financial Officer Common Stock 2019-03-20 4 S 0 857 7.99 D 24603 D Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. The shares were sold at prices ranging from $7.94 to $8.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Jennifer Rhodes, Attorney-in-fact 2019-03-21